

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Janku Filip</u> (Last) (First) (Middle) MONTE ROSA THERAPEUTICS, INC. 321 HARRISON AVENUE, SUITE 900 (Street) BOSTON MA 02118 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Monte Rosa Therapeutics, Inc. [GLUE]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Medical Officer
	3. Date of Earliest Transaction (Month/Day/Year) 06/23/2026	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/23/2026		M ⁽¹⁾		6,000	A	\$7.56	71,837	D	
Common Stock	06/23/2026		S ⁽¹⁾		11,845	D	\$20.2214 ⁽²⁾	59,992	D	
Common Stock	06/24/2026		M ⁽¹⁾		30,000	A	\$7.56	89,992	D	
Common Stock	06/24/2026		S ⁽¹⁾		30,000	D	\$21.4227 ⁽³⁾	59,992	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock Option (Right to Buy)	\$7.56	06/23/2026		M ⁽¹⁾		6,000		(4)	10/03/2032	Common Stock	6,000	\$0	96,000	D	
Stock Option (Right to Buy)	\$7.56	06/24/2026		M ⁽¹⁾		30,000		(4)	10/03/2032	Common Stock	30,000	\$0	66,000	D	

Explanation of Responses:

- These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$19.95 to \$20.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$21.30 to \$21.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- The shares underlying this option are fully vested and exercisable.

Remarks:

Exhibit 24.2 - Substitute Power of Attorney

/s/ Phil Nickson, Attorney-in-Fact 06/25/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SUBSTITUTE POWER OF ATTORNEY

Under the terms of powers of attorney (each, a “Power of Attorney”) previously filed with the U.S. Securities and Exchange Commission, the undersigned was appointed an attorney-in-fact for the below listed individuals to, among other things, execute for and on behalf of the following individuals any Forms 3, 4 or 5, Schedule 13D or 13G, or any amendment(s) thereto, in accordance with Section 13 or Section 16 of the Securities Exchange Act of 1934, as amended, and the rules thereunder:

Filip Janku
Kimberly Blackwell
Chandra Leo
Anthony Manning
Andrew Schiff
Christine Siu
Jan Skvarka

In addition, the undersigned has executed a Power of Attorney in his individual capacity covering the matters described above. In accordance with the authority granted under each Power of Attorney, including the full power of substitution, the undersigned hereby appoints Phil Nickson as substitute attorney-in-fact, on behalf of himself and on behalf of the individuals listed above, with the power to exercise and execute all of the powers granted or conferred in the applicable Power of Attorney. For the avoidance of doubt, the foregoing appointment shall not serve as a revocation of the powers granted to the undersigned himself in each Power of Attorney.

This substitute Power of Attorney shall remain in full force and effect with respect to each Power of Attorney until such underlying Power of Attorney is revoked or terminated, unless earlier revoked by the undersigned in a signed writing.

Date: June 24, 2026

By: /s/ Markus Warmuth
Name: Markus Warmuth
Title: Attorney-in-Fact
